Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider And Smart Money Move Into Corbus Pharmaceuticals As Pipeline Progresses

Page 1 of 3

For institutional holders, the biggest gains in terms of percentage per holding are made in the smaller companies. For obvious reasons, a hedge fund cannot exclusively rely on small-cap gains and usually save the bulk of their capital for more traditional investments. It is impossible to sink many millions of dollars in a company with a market cap in the tens of millions. Nevertheless, following the small-cap positions of the big players and their respective insiders can help increase the success rate of small-cap picks.

Over the last quarter, we’ve seen a large amount of activity in both insider and institutional buying related to a small-cap biotech called Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP). While these stocks are notoriously risky, by following the lead of both insiders and institutions, it’s possible to mitigate this risk. With Corbus, the increase in insider and institutional holdings is coming at a time when the company is just beginning to dose patients in three separate phase II efficacy trials for its flagship candidate, Resunab.

Corbus is focusing almost entirely on Resunab. The drug is currently undergoing three phase II trials in three separate indications – cystic fibrosis, systemic sclerosis and dermatomyositis. We’ll look at the trials individually shortly, but before that, let’s look at the drug and its mechanism of action.

Resunab is what’s called an endocannabinoid-mimetic drug, which essentially means it is a synthesized drug that targets the endocannabinoid system. This system consists of receptors in our brains and nervous systems that control and regulate inflammation and immune response, among other things. When the immune system responds to a pathogen, one of the most common responses is inflammation. Inflammation is usually beneficial short term as it concentrates immune cells to a particular area, but in certain diseases, it is detrimental and overexpressed, leading to debilitating symptoms such as the fibrosis in cystic fibrosis sufferers.

With Resunab, Corbus is attempting to switch off the inflammation process. It does so by activating the CB2 receptor, which is one of the cannabinoid receptors that make up the endocannabinoid system. The CB2 receptor is found on the surface of nearly every immune cell.

Without letting the confusing abbreviations deter us from understanding the drug, activating the CB2 receptor activates signaling molecules called eicosanoids. Two of them, PGE2 and LTB4, are responsible for inflammation. Another two, PGJ2 and LXA4, are responsible for tissue healing. We know that activating the CB2 receptor increases the production of the tissue-healing molecules and decreases the production of inflammatory eicosanoids. That means less inflammation and more tissue healing.

While all CB2 agonist molecules elicit this response, Corbus’s trump card is that Resunab is up to 100x more potent than the naturally occurring cannabinoids meant to pull off the same job. That means Resunab could be especially effective in stopping the inflammatory cycle in patients where inflammation only hurts the underlying disease rather than helping it.

As for the specific trials, Corbus kicked off a phase II in cystic fibrosis in October this year announcing the first dosing on October 15. The trial is operating at 20 sites split across the US and Europe totaling 70 patients with a primary endpoint of safety and tolerability. It’s a relatively short trial, which is common in these early, dose escalation trials, and top-line results are expected by December 2016, exactly one year from now. Corbus is sponsoring this trial so we can expect cash burn rate to rise next year.

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!